Thermo Fisher Scientific Inc (NYSE:TMO) posted its quarterly earnings data on Wednesday. The medical research company reported $2.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.26 by $0.04, Bloomberg Earnings reports. Thermo Fisher Scientific had a return on equity of 15.73% and a net margin of 11.58%. The firm had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. During the same period in the previous year, the firm earned $2.03 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis.

Thermo Fisher Scientific (NYSE TMO) traded down 3.2868% during mid-day trading on Wednesday, reaching $174.2095. The company’s stock had a trading volume of 1,512,113 shares. The firm’s 50 day moving average is $176.72 and its 200-day moving average is $162.85. The company has a market cap of $68.15 billion, a PE ratio of 31.7785 and a beta of 1.06. Thermo Fisher Scientific has a 12-month low of $139.07 and a 12-month high of $182.87.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 10.95%.

TRADEMARK VIOLATION NOTICE: “Thermo Fisher Scientific Inc (NYSE:TMO) Posts Earnings Results, Beats Estimates By $0.04 EPS” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/26/thermo-fisher-scientific-inc-nysetmo-posts-earnings-results-beats-estimates-by-0-04-eps.html.

A number of research analysts have recently weighed in on the company. Jefferies Group LLC lifted their price objective on Thermo Fisher Scientific from $160.00 to $175.00 and gave the company a “hold” rating in a research report on Friday, April 28th. Deutsche Bank AG set a $200.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Saturday, June 10th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $200.00 price objective (up from $195.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 13th. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Finally, Bank of America Corporation reaffirmed a “buy” rating and set a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. One research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $187.88.

In related news, insider Thomas W. Loewald sold 1,532 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $168.76, for a total transaction of $258,540.32. Following the transaction, the insider now owns 41,277 shares in the company, valued at $6,965,906.52. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $176.26, for a total value of $440,650.00. Following the transaction, the chief financial officer now owns 37,790 shares in the company, valued at approximately $6,660,865.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,720 shares of company stock worth $4,960,764. Company insiders own 0.49% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Campbell & CO Investment Adviser LLC increased its position in shares of Thermo Fisher Scientific by 113.2% in the second quarter. Campbell & CO Investment Adviser LLC now owns 7,459 shares of the medical research company’s stock worth $1,301,000 after buying an additional 3,961 shares during the last quarter. Aviance Capital Partners LLC increased its position in shares of Thermo Fisher Scientific by 3.3% in the second quarter. Aviance Capital Partners LLC now owns 10,827 shares of the medical research company’s stock worth $1,889,000 after buying an additional 350 shares during the last quarter. Smith Salley & Associates increased its position in shares of Thermo Fisher Scientific by 1,159.7% in the second quarter. Smith Salley & Associates now owns 27,449 shares of the medical research company’s stock worth $4,789,000 after buying an additional 25,270 shares during the last quarter. Lodestar Investment Counsel LLC IL increased its position in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Lodestar Investment Counsel LLC IL now owns 71,439 shares of the medical research company’s stock worth $12,464,000 after buying an additional 1,111 shares during the last quarter. Finally, SeaBridge Investment Advisors LLC increased its position in shares of Thermo Fisher Scientific by 1.7% in the second quarter. SeaBridge Investment Advisors LLC now owns 19,304 shares of the medical research company’s stock worth $3,368,000 after buying an additional 326 shares during the last quarter. Hedge funds and other institutional investors own 87.05% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Earnings History for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.